We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

10 hedge funds and large institutions have $249K invested in Galmed Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% less ownership

Funds ownership: 0.19% → 0.15% (-0.04%)

17% less funds holding

Funds holding: 12 → 10 (-2)

42% less capital invested

Capital invested by funds: $429K → $249K (-$180K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$24.8K
2
CH
CVI Holdings
Delaware
+$7.89K

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$53.4K
2
VF
Virtu Financial
New York
-$18K
3
Millennium Management
Millennium Management
New York
-$12.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$11.6K
5
Two Sigma Investments
Two Sigma Investments
New York
-$2.86K

GLMD Hedge Fund Activity: Q4 2023 in Review

10 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2023, worth a combined $249K — down 42% from $429K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of GLMD and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $24.8K. The largest seller was Walleye Capital, cutting an estimated $53.4K.

  • 10 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2023, down from 12 in Q3 2023.
  • Funds reported $249K of Galmed Pharmaceuticals stock for Q4 2023, down 42% quarter-over-quarter.
  • 0 funds opened new Galmed Pharmaceuticals positions in Q4 2023 and 2 closed out, a net change of -2 holders.
  • The largest Galmed Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $24.8K added.
  • The largest Galmed Pharmaceuticals seller in Q4 2023 was Walleye Capital, an estimated $53.4K sold.

Based on aggregated 13F filings for Q4 2023.